Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of EGFR and MET has a synergistic effect on the prognosis of patients with oral squamous cell carcinoma.
|
31762177 |
2020 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The likely presence of E5 transcripts was neither associated to a higher activity of the EGFR-VEGFA pathway nor to the overall survival of patients with HPV16+ squamous cell carcinoma in stages ≥ IB2.This article is protected by copyright.All rights reserved.
|
31696949 |
2019 |
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Paired genomic analysis from our sample provides early clinical evidence of the ADC to SCC lineage transition that might be provoked by an alteration in the PI3K/AKT/mTOR pathway during EGFR TKI treatment.
|
31319998 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of ADAM10 in oral squamous cell carcinoma and its correlation with EGFR, neoangiogenesis and clinicopathologic factors.
|
31395417 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The anti-human epidermal growth factor receptor IgG conjugated to ZZ-BNC (α-hEGFR-ZZ-BNC) was endocytosed by the human epidermoid carcinoma A431 cells, with increases in cellular uptake by ∼1.5 fold, compared that of α-hEGFR IgG alone.
|
30641288 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas.
|
31320902 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China.
|
31556771 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Similarly, EGFR inhibitor demonstrated marginal success in unresectable cutaneous squamous cell carcinomas.
|
30045105 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.
|
30907457 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.
|
31035951 |
2019 |
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that EGFR mutations were more prevalent in never-smokers (83.3% versus 16.7%, p = 0.006) and patients diagnosed as NSCC favor SqCC (46.2% versus 5.2%, p = 0.001).
|
31221183 |
2019 |
Squamous cell carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Interestingly, in human NSCLCs, phosphorylation of EGFR or ERBB3 was frequently detected in ASCs and squamous cell carcinomas.
|
31320402 |
2019 |
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of the 196 non-squamous carcinomas, 35% had rat sarcoma viral oncogene homolog (RAS) mutations, 13% had epidermal growth factor receptor (EGFR) mutations, 2% had anaplastic lymphoma kinase (ALK) translocations and 2% had ROS1 translocations.
|
30401947 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Immune cell infiltrates from LUAD and LUSC tumors differed according to EGFR expression.
|
31746315 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The favor ADC group tended to have a higher percentage of EGFR positivity and ALK positivity than the favor SQC group (25% vs. 11% and 7% vs. 0%, respectively).
|
31494736 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We also show that EGFR is frequently expressed in DEB-associated SCCs, although there were noticeable differences in the level of expression, which may influence responsiveness to EGFR-targeting therapies.
|
31796084 |
2019 |
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since this first description of SqCC transformation appearing after treatment with the third-generation TKI osimertinib, other 16 patients, with EGFR-mutated ADK developing a transformation to SqCC histology after treatment with TKIs, were up to now published.
|
30642539 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
There was no association between HGF, cMET, EGF, EGFR (both protein and gene) expression levels with age, gender, smoking habit, COPD, pathological types or tumor size, stage, metastatic-non metastatic adenocarcinoma-squamous carcinoma, SCLC-NSCLC.
|
31104010 |
2019 |
Squamous cell carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our results suggest that a small subset of these tumours could be related to HPV infection; EGFR mutations characterise those ISPs with a lower risk of developing into SCC; LINE-1 hypomethylation is associated with occupational exposure and could identify more aggressive nasal SCC.
|
30411788 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Significance:</b> This article confirms the importance of EGFR expression as a biomarker in laryngeal SCC.
|
31430224 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes.
|
30077724 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The relationship between laminin γ 2 chain gene (LAMC2) and epidermal growth factor receptor (EGFR) has been previously documented in gastric cancer and oral squamous cell carcinoma.
|
31345467 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since one of the most common resistance mechanisms against EGFR inhibition relies on the activation of cMET parallel signaling, we investigated the efficacy of a dual blockade with erlotinib and crizotinib in EGFR and cMET wild-type lung SCC cell lines.
|
31078602 |
2019 |
Squamous cell carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ADC histogram parameters might be able to reflect expression of EGFR and histone 3 in cervical squamous cell carcinomas, but not expression of VEGF, Hif1-alpha and Her2.
|
30367998 |
2019 |
Squamous cell carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that co-targeting EGFR and IKKβ with Gefitinib and IKKβ inhibitors could provide a potential novel therapy for head and neck squamous cell cancer.
|
30585254 |
2019 |